Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
- 1 July 2015
- journal article
- research article
- Vol. 8 (7) , 8487-93
Abstract
The study compares detection rates of oncogenic BRAF mutations in a homogenous group of 236 FFPE cutaneous melanoma lymph node metastases, collected in one cancer center. BRAF mutational status was verified by two independent in-house PCR/Sanger sequencing tests, and the Cobas® 4800 BRAF V600 Mutation Test. The best of two sequencing approaches returned results for 230/236 samples. In 140 (60.9%), the mutation in codon 600 of BRAF was found. 91.4% of all mutated cases (128 samples) represented p.V600E. Both Sanger-based tests gave reproducible results although they differed significantly in the percentage of amplifiable samples: 230/236 to 109/143. Cobas generated results in all 236 cases, mutations changing codon V600 were detected in 144 of them (61.0%), including 5 not amplifiable and 5 negative in the standard sequencing. However, 6 cases positive in sequencing turned out to be negative in Cobas. Both tests provided us with the same BRAF V600 mutational status in 219 out of 230 cases with valid results (95.2%). The total BRAF V600 mutation detection rate didn't differ significantly between the two methodological approaches (60.9% vs. 61.0%). Sequencing was a reproducible method of V600 mutation detection and more powerful to detect mutations other than p.V600E, while Cobas test proved to be less susceptible to the poor DNA quality or investigator's bias. The study underlined an important role of pathologists in quality assurance of molecular diagnostics.Keywords
This publication has 25 references indexed in Scilit:
- Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcomeOncology Letters, 2014
- Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in MelanomaMolecular Diagnosis & Therapy, 2014
- Molecular Platforms Utilized to Detect BRAF V600E Mutation in MelanomaSeminars in Cutaneous Medicine and Surgery, 2012
- Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant MelanomaArchives of Pathology & Laboratory Medicine, 2012
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic MelanomaClinical Cancer Research, 2012
- KRAS and BRAF Mutation Analysis in Routine Molecular DiagnosticsThe Journal of Molecular Diagnostics, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastasesActa Neuropathologica, 2011
- Comparison of Allelic Discrimination by dHPLC, HRM, and TaqMan in the Detection of BRAF Mutation V600EThe Journal of Molecular Diagnostics, 2011
- Mutations of the BRAF gene in human cancerNature, 2002